[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Sassa N, Yoshino Y, Matsukawa Y, Komatsu T, Yoshikawa Y, Yamamoto T, Hattori R, Gotoh M: [Case report of malignant sertoli cell tumor]. Nihon Hinyokika Gakkai Zasshi; 2008 Jul;99(5):656-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 38-year-old male visited a hospital with a complaint of swelling his left testis.
  • His pathologic diagnosis was suspected seminoma, and all tumor markers (LDH, HCG, AFP) were negative, and CT imaging confirmed clinical stage 1 (pT1N0M0S0).
  • He received 3 courses of chemotherapy with BEP (bleomycine, etoposide, cisplatin), but, lymph node size did not change.
  • After he underwent a CT guided lymph node biopsy, his pathologic diagnosis was viable embryonal carcinoma.
  • We selected CPT-11 and nedaplatin for his salvage chemotherapy, but lymph node lesions did not change.
  • After he received 3 courses of chemotherapy, we performed retroperitoneal lymphadenectomy.
  • His pathologic diagnosis was viable sertoli cell tumor, malignant type.
  • [MeSH-major] Sertoli Cell Tumor / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Combined Modality Therapy. Fatal Outcome. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Orchiectomy. Organoplatinum Compounds / administration & dosage. Salvage Therapy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18697473.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Organoplatinum Compounds; 7673326042 / irinotecan; 8UQ3W6JXAN / nedaplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


2. Shoji S, Shima M, Usui Y, Nagata Y, Uchida T, Terachi T: [A case report: simultaneous bilateral testicular tumors with different cell types--complete response after combination chemotherapy of cisplatin and irrinotecan hydrochloride--]. Hinyokika Kiyo; 2006 Apr;52(4):303-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report: simultaneous bilateral testicular tumors with different cell types--complete response after combination chemotherapy of cisplatin and irrinotecan hydrochloride--].
  • On examination, the patient was found to have bilateral testicular tumors with jugular chain lymph node and para-aortic lymph node metastasis.
  • Histopathological examination of the excised tumors revealed seminoma, embryonal carcinoma, yolk sac tumor and immature teratoma in the right testis and seminoma in the left testis.
  • The patient was treated postoperatively with two courses of BEP (bleomycin, etoposide, cisplatin) therapy and two courses of EP (etoposide, cisplatinum) therapy.
  • The patient had lung metastasis during the follow-up period and we treated him with salvage combination chemotherapy of cisplatin and irinotecan hydrochloride (CPT-11).
  • After the third course of cisplatin and CPT-11 chemotherapy the lung metastasis disappeared and we performed retroperitoneal lymph node dissection.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endodermal Sinus Tumor / drug therapy. Neoplasms, Multiple Primary. Salvage Therapy. Seminoma / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Humans. Lung Neoplasms / secondary. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Remission Induction

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16686361.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


3. Kita M, Sasaki Y, Okuyama M, Saga Y, Hashimoto H, Kaneko S, Yachiku S, Tokumitsu M, Inada F, Ishida H: [Pulmonary rhabdomyosarcoma generated during treatment of testicular tumor]. Nihon Hinyokika Gakkai Zasshi; 2003 Nov;94(7):696-700
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary rhabdomyosarcoma generated during treatment of testicular tumor].
  • He had undergone right high orchiectomy, chemotherapy with four courses of PEB regimen (cisplatin, etoposide, bleomycin) and retroperitoneal lymph node dissection the previous year.
  • The pathological findings showed mixed germ cell tumor (seminoma, yolk sac tumor, embryonal carcinoma) in the testis and mature teratoma in the draining lymph node.
  • Two courses of salvage chemotherapy using a VIP regimen (etoposide, ifosfamide, cisplatin) were performed after diagnosis of pulmonary metastases, but had no affect on tumor size.
  • The operation was followed by three courses of CYVADIC (cyclophosphamide, vincristine, adriamycin, dacarbazin) chemotherapy and oral cyclophosphamide, as a small residual tumor was suspected.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / secondary. Rhabdomyosarcoma / secondary. Testicular Neoplasms / therapy
  • [MeSH-minor] Adult. Carcinoma, Embryonal / pathology. Carcinoma, Embryonal / therapy. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / therapy. Etoposide / administration & dosage. Humans. Ifosfamide / administration & dosage. Lymph Node Excision. Male. Orchiectomy. Pneumonectomy. Seminoma / pathology. Seminoma / therapy. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14672002.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; CYVADIC protocol; ICE protocol 1
  • [Number-of-references] 15
  •  go-up   go-down


Advertisement
4. Saito M, Shimoda N, Terai Y, Akihama S, Iinuma M, Mitsumori K, Ohyama C, Satoh S, Sato K, Habuchi T, Kato T: [A case of organ sparing surgery for metachronous bilateral testicular tumor with maintaining testicular function]. Nihon Hinyokika Gakkai Zasshi; 2004 Mar;95(3):621-5
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of organ sparing surgery for metachronous bilateral testicular tumor with maintaining testicular function].
  • A 28-year-old man, who had undergone right orchiectomy and prophylactic irradiation for stage I seminoma 6 years ago, developed left testicular tumor.
  • Since the secondary tumor was localized in the lower pole of the testis, partial orchiectomy was performed with an attempt to preserve the testicular function.
  • The pathological finding of the surgical specimen was a mixed type testicular tumor consisting of seminoma, embryonal carcinoma and teratoma elements.
  • Postoperative chemotherapy with 3 courses of BEP regimen resulted in azoospermia, but the impaired spermatogenesis recovered to a normal range within 18 months with no evidence of tumor recurrence and his wife delivered a healthy baby 2 years later.
  • For the synchronous or metachronous bilateral testicular tumors, the combination of organ sparing surgery and chemotherapy could be a treatment of choice.
  • [MeSH-major] Carcinoma, Embryonal / surgery. Fertility. Neoplasms, Second Primary. Orchiectomy / methods. Seminoma / surgery. Teratoma / surgery. Testicular Neoplasms / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Etoposide / administration & dosage. Etoposide / adverse effects. Humans. Male. Oligospermia / chemically induced. Testis / physiology. Testis / physiopathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15103926.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  • [Number-of-references] 20
  •  go-up   go-down


5. Basu S, Rubello D: PET imaging in the management of tumors of testis and ovary: current thinking and future directions. Minerva Endocrinol; 2008 Sep;33(3):229-56
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PET imaging in the management of tumors of testis and ovary: current thinking and future directions.
  • The role of fluoro-D-deoxyglucose positron-emission tomography (FDG-PET) in testicular malignancies has been examined in various studies primarily in three specific settings:.
  • 1) differentiation of active disease from fibrosis/mature teratoma in patients with residual mass following chemotherapy and evaluation of the response to treatment;.
  • 2) initial staging and disease assessment after orchidectomy identification of suspected recurrences in the context of elevated circulating serum markers; and 3) predicting response to treatment.
  • Of these, the area where FDG-PET imaging has been examined the most in testicular tumors is the evaluation of postchemotherapy residual mass in both seminoma and nonseminomatous germ cell tumors (NSGCT) of the testis, a critical step in determining the subsequent management approach of these tumors that vary amongst various centers.
  • From the available data, this should be the test of choice for the assessment of a computed tomography (CT)-visualized residual mass following chemotherapy.
  • In patients with residual masses or raised marker levels following therapy, positron-emission tomography (PET) appears sensitive and specific for detecting recurrent disease, at suspected and unsuspected sites.
  • With regard to its role in ovarian carcinoma, it appears to be particularly useful for the diagnosis of recurrence when CA125 levels are rising and conventional imaging is inconclusive or negative.
  • The role of fluoro-D-deoxyglucose (FDG)-PET/CT for the detection of recurrent ovarian cancer appears very promising and has the potential to replace the current surveillance techniques in detecting recurrent disease.
  • [MeSH-major] Ovarian Neoplasms / radionuclide imaging. Positron-Emission Tomography. Testicular Neoplasms / radionuclide imaging
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Cost-Benefit Analysis. Female. Follow-Up Studies. Forecasting. Humans. Lymphoma, Non-Hodgkin / radionuclide imaging. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Neoplasm Staging / methods. Neoplasms, Germ Cell and Embryonal / radionuclide imaging. Neoplasms, Germ Cell and Embryonal / therapy. Paraneoplastic Cerebellar Degeneration / radionuclide imaging. Prognosis. Prospective Studies. Radiopharmaceuticals. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18846028.001).
  • [ISSN] 0391-1977
  • [Journal-full-title] Minerva endocrinologica
  • [ISO-abbreviation] Minerva Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Radiopharmaceuticals
  • [Number-of-references] 83
  •  go-up   go-down


6. Emerson RE, Ulbright TM: Intratubular germ cell neoplasia of the testis and its associated cancers: the use of novel biomarkers. Pathology; 2010 Jun;42(4):344-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratubular germ cell neoplasia of the testis and its associated cancers: the use of novel biomarkers.
  • Recent advances in the understanding of the molecular pathology of testicular tumours have led to the identification of several new immunohistochemical markers for invasive and in situ germ cell neoplasms.
  • OCT3/4 and NANOG are nuclear stains that have high sensitivity and specificity for the identification of intratubular germ cell neoplasia as well as seminoma and embryonal carcinoma.
  • A potential pitfall in their application to the detection of intratubular germ cell neoplasia, as in other markers that represent oncofetal antigens, is their expression in non-neoplastic germ cells with 'delayed maturation'.
  • SALL4, another nuclear stain, is positive for most germ cell tumours as a group and may be especially helpful in the distinction of these tumours from somatic carcinomas in non-testicular sites.
  • SOX2 and SOX17 may be useful for differentiating seminoma and embryonal carcinoma, especially following chemotherapy as embryonal carcinoma may lose CD30 expression in this setting.
  • Suggested immunohistochemical panels are described for individual tumour types.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Neoplasms, Germ Cell and Embryonal / metabolism. Testicular Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20438407.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 96
  •  go-up   go-down


7. Ugwumba FO, Aghaji AE: Testicular cancer: Management challenges in an African developing country. S Afr Med J; 2010 Jul;100(7):452-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular cancer: Management challenges in an African developing country.
  • BACKGROUND: Advances in oncology have greatly improved the prognosis of testicular cancer.
  • PATIENTS AND METHODS: Twenty-four patients managed for testicular cancer at two centres (University of Nigeria Teaching Hospital, Enugu, Nigeria, and JAMA Urological Clinic, Enugu) between April 1984 and March 2003 were prospectively studied.
  • Testicular swelling was the principal complaint in 23 patients.
  • Treatment consisted of radical orchidectomy in all patients and cisplatin-based chemotherapy and radiotherapy in some patients.
  • One patient with a tumour in an intra-abdominal testis underwent laparotomy.
  • The most common histological types were seminoma and embryonal carcinoma.
  • CONCLUSION: Morbidity and mortality of testicular cancer is high in developing countries.
  • Late presentation, poverty, paucity of resources and the high cost of newer imaging modalities and treatment are major challenges to management.
  • Better health funding and education regarding testicular self-examination is essential.
  • [MeSH-major] Testicular Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Africa. Antineoplastic Agents / therapeutic use. Carcinoma, Embryonal / pathology. Child. Cisplatin / therapeutic use. Combined Modality Therapy. Developing Countries. Follow-Up Studies. Humans. Laparotomy. Male. Middle Aged. Orchiectomy. Seminoma / pathology

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20822594.001).
  • [ISSN] 0256-9574
  • [Journal-full-title] South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
  • [ISO-abbreviation] S. Afr. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] South Africa
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Berney DM, Shamash J, Gaffney J, Jordan S, Oliver RT: DNA topoisomerase I and II expression in drug resistant germ cell tumours. Br J Cancer; 2002 Sep 9;87(6):624-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA topoisomerase I and II expression in drug resistant germ cell tumours.
  • A small number of testicular germ cell tumours are refractory to current chemotherapy regimens.
  • DNA topoisomerase I is the target for several new drugs and a potential candidate treatment for chemorefractory germ cell tumours.
  • DNA topoisomerase II alpha is the target for etoposide, which is currently used regularly in germ cell tumour treatment.
  • The expression of DNA topoisomerase I and II alpha were therefore assessed immunohistochemically in a range of testicular tumours, especially those with persistent malignant elements on retroperitoneal lymph node dissection.
  • Pre-chemotherapy orchidectomy specimens were matched with post-chemotherapy retroperitoneal lymph node dissections to examine changes in expression.
  • There was considerable variation in the expression of topoisomerase I in different tumour types.
  • Both yolk sac tumours and teratoma, mature showed universal expression of topoisomerase I, while 38% of seminomas and 30% of embryonal carcinomas were positive.
  • Strong topoisomerase II alpha expression was found in embryonal carcinoma.
  • There was a negative correlation between topoisomerase I and II alpha expression (P=0.004) and downregulation of topoisomerase II alpha after chemotherapy (P=0.02).
  • Topoisomerase I expression appears to increase in those cases with residual teratoma, mature, but is largely unchanged in those cases remaining as embryonal carcinoma.
  • [MeSH-major] Carcinoma, Embryonal / metabolism. DNA Topoisomerases, Type I / metabolism. DNA Topoisomerases, Type II / metabolism. Drug Resistance, Neoplasm. Seminoma / metabolism. Teratoma / metabolism. Testicular Neoplasms / metabolism
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Case-Control Studies. Cisplatin / administration & dosage. Down-Regulation. Etoposide / administration & dosage. Humans. Immunoenzyme Techniques. Ki-67 Antigen / metabolism. Male. Testis / chemistry. Testis / pathology

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] APMIS. 2000 Mar;108(3):209-15 [10752690.001]
  • [Cites] Hum Pathol. 2000 Feb;31(2):214-9 [10685636.001]
  • [Cites] Hum Pathol. 2000 Jun;31(6):728-33 [10872667.001]
  • [Cites] Lab Invest. 2000 Jun;80(6):787-95 [10879730.001]
  • [Cites] J Urol. 2000 Aug;164(2):381-4 [10893590.001]
  • [Cites] Brain Tumor Pathol. 2000;17(1):7-13 [10982004.001]
  • [Cites] Br J Cancer. 2001 Feb 2;84(3):340-3 [11161398.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2647-57 [11352956.001]
  • [Cites] Histopathology. 2001 Oct;39(4):382-5 [11683938.001]
  • [Cites] Anticancer Res. 2001 Jul-Aug;21(4B):2925-32 [11712788.001]
  • [Cites] Cancer. 1981 Aug 15;48(4):904-8 [6168361.001]
  • [Cites] Br J Cancer. 1984 Nov;50(5):601-9 [6093838.001]
  • [Cites] N Engl J Med. 1987 Dec 3;317(23):1433-8 [2446132.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):6919-24 [1698546.001]
  • [Cites] Cancer Res. 1992 Feb 1;52(3):525-32 [1310066.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1294-9 [8391067.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):120-6 [7505805.001]
  • [Cites] Cancer Res. 1994 Jan 15;54(2):539-46 [8275492.001]
  • [Cites] J Urol. 1994 Oct;152(4):1144-9 [8072083.001]
  • [Cites] Int J Cancer. 1994 Dec 1;59(5):607-11 [7960233.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2129-34 [7743513.001]
  • [Cites] Br J Cancer. 1995 Dec;72(6):1454-61 [8519659.001]
  • [Cites] Anticancer Res. 1995 Sep-Oct;15(5B):2117-20 [8572612.001]
  • [Cites] J Cell Biol. 1996 Aug;134(3):757-70 [8707853.001]
  • [Cites] Annu Rev Biochem. 1996;65:635-92 [8811192.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):594-603 [9053482.001]
  • [Cites] Eur Urol. 1997;31(1):92-6 [9032542.001]
  • [Cites] Cancer Res. 1997 Apr 15;57(8):1425-8 [9108439.001]
  • [Cites] Nucleic Acids Res. 1997 Nov 1;25(21):4181-6 [9336444.001]
  • [Cites] Cancer Res. 1997 Dec 15;57(24):5475-9 [9407953.001]
  • [Cites] Mol Pathol. 1997 Oct;50(5):247-53 [9497914.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2500-4 [9667270.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):107-19 [9748525.001]
  • [Cites] Hum Pathol. 1999 Apr;30(4):384-91 [10208458.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):685-92 [10442191.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4237-41 [10485464.001]
  • [Cites] Ann Oncol. 1998 Mar;9(3):313-9 [9602266.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):257-73 [10680894.001]
  • [Cites] Hum Pathol. 2000 Jun;31(6):631-2 [10872653.001]
  • (PMID = 12237772.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 6PLQ3CP4P3 / Etoposide; EC 5.99.1.2 / DNA Topoisomerases, Type I; EC 5.99.1.3 / DNA Topoisomerases, Type II; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2364243
  •  go-up   go-down


9. Denissen NH, van Spronsen DJ, Smilde TJ, De Mulder PH: Leptomeningeal carcinomatosis in relapsed non-seminoma testis: a 1-year complete remission with high-dose chemotherapy. Anticancer Drugs; 2005 Sep;16(8):897-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal carcinomatosis in relapsed non-seminoma testis: a 1-year complete remission with high-dose chemotherapy.
  • A 1-year complete remission could be achieved with high-dose systemic chemotherapy in a 33-year-old patient with relapsed germ cell tumor presenting with leptomeningeal carcinomatosis (LC).
  • Although LC in general has a very poor prognosis for patients with chemosensitive malignancies, systemic chemotherapy should be considered.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Meningeal Neoplasms / drug therapy. Neoplasms, Germ Cell and Embryonal / drug therapy. Salvage Therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Humans. Male. Neoplasm Recurrence, Local / drug therapy. Remission Induction

  • Genetic Alliance. consumer health - Seminoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16096440.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Amato RJ, Ro JY, Ayala AG, Swanson DA: Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis. Urology; 2004 Jan;63(1):144-8; discussion 148-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis.
  • OBJECTIVES: To evaluate whether two courses of chemotherapy after orchiectomy in patients with clinical Stage I nonseminomatous germ cell testicular tumor at high risk of relapse will spare patients additional chemotherapy or surgery.
  • METHODS: High-risk patients had one or more of the following: preorchiectomy alpha-fetoprotein level of 80 ng/dL or greater, 80% embryonal cell carcinoma or greater, or vessel invasion in the primary tumor.
  • High-risk patients were offered two 21-day courses of outpatient chemotherapy consisting of carboplatin, etoposide, and bleomycin.
  • Low-risk patients and high-risk patients not receiving chemotherapy were observed.
  • All but eight of the high-risk patients received chemotherapy.
  • No patient who underwent chemotherapy developed relapse, although 1 patient with normal biomarkers and a late-appearing mass underwent retroperitoneal lymphadenectomy for mature teratoma.
  • Two of the 23 low-risk patients had disease relapse; both successfully underwent chemotherapy.
  • The nonhematologic toxicity was mild in patients receiving chemotherapy, and no patient required hospitalization.
  • CONCLUSIONS: Two courses of postorchiectomy adjuvant chemotherapy were safe and well tolerated and markedly decreased the relapse rate in high-risk patients with clinical Stage I nonseminomatous germ cell testicular tumor without additional surgery or more protracted chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Germinoma / drug therapy. Orchiectomy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Biomarkers, Tumor / blood. Bleomycin / administration & dosage. Carboplatin / administration & dosage. Carcinoma, Embryonal / drug therapy. Carcinoma, Embryonal / pathology. Carcinoma, Embryonal / surgery. Combined Modality Therapy. Disease-Free Survival. Drug Administration Schedule. Etoposide / administration & dosage. Humans. Lymph Node Excision. Male. Neoplasm Invasiveness. Neoplasm Proteins / analysis. Neoplasm Staging. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / surgery. Prognosis. Risk Factors. Seminoma / drug therapy. Seminoma / pathology. Seminoma / surgery. Teratoma / drug therapy. Teratoma / pathology. Teratoma / surgery. Treatment Outcome. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Nonseminomatous germ cell tumor.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14751368.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / alpha-Fetoproteins; 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


11. Mickisch GH: Prognostic parameters for the management of advanced testis tumours. Curr Opin Urol; 2000 Sep;10(5):465-71
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic parameters for the management of advanced testis tumours.
  • The need for prognostic parameters in testicular germ cell tumours is sometimes questioned based on an overall cure rate of more than 80% of the patients regardless of tumour stage.
  • However, the trend for an earlier and more accurate diagnosis amenable to curative treatment as well as the high effectiveness of standard Cisplatinum containing chemotherapy has masked the continuing need for intensifying therapy in patients with adverse risk factors.
  • This intense treatment is often associated with worrysome morbidity and the assessment of prognostic factors, stage by stage, is warranted on which patient at risk can be identified and treated accordingly.
  • Clearly, the infrastructure and the experience of the treating uro-oncology unit (see 1) is decisive for treatment outcomes, and -at least-'difficult to treat' patients should be referred to properly resourced cancer centres.
  • Finally, biologic factors (see 3) such as beta-human chorionic gonadotrophin or MAGE epitopes in seminoma or the percentage of embryonal carcinoma components orvascular invasion mayor may not inversely influence the prognosis and need further assessment in prospective trials.
  • However, the search for even better (molecular) biologic factors is speeding up because more complex treatment decisions such as in advanced testicular cancers rely on a more precise determination of prognosis, enabling a more tailored selection of individualized therapeutic options.
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasms, Germ Cell and Embryonal / pathology. Testicular Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11005453.001).
  • [ISSN] 0963-0643
  • [Journal-full-title] Current opinion in urology
  • [ISO-abbreviation] Curr Opin Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 23
  •  go-up   go-down


12. Melchior D, Müller SC, Albers P: Extensive surgery in metastatic testicular cancer. Aktuelle Urol; 2003 Jul;34(4):214-22
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive surgery in metastatic testicular cancer.
  • Surgery remains an important component in the multimodal treatment of patients with advanced testicular cancer.
  • Recently, however, the indications for post-chemotherapy residual tumor resection have changed.
  • Patients with advanced seminoma very rarely need surgical resection of the residual disease after standard chemotherapy.
  • In contrast, patients with high stage non-seminomatous testis cancer must undergo post-chemotherapy surgery in most cases.
  • Surgical resection in metastatic disease may also be necessary in patients with recurrent tumors, patients with persisting marker elevation during chemotherapy and patients with late relapses.
  • Post-chemotherapy residual tumor resections, "redo"-retroperitoneal tumor operations and other salvage resections are often technically demanding procedures with unusual surgical approaches that require individualized perioperative planning in order to reduce morbidity.
  • This paper summarizes the current indications for post-chemotherapy surgery and discusses various surgical approaches and techniques, perioperative management recommendations, as well as complications of these extensive resection procedures.
  • [MeSH-major] Carcinoma, Embryonal / surgery. Germinoma / surgery. Seminoma / surgery. Teratoma / surgery. Testicular Neoplasms / surgery
  • [MeSH-minor] Adult. Combined Modality Therapy. Follow-Up Studies. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Testicular cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14566667.001).
  • [ISSN] 0001-7868
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 52
  •  go-up   go-down


13. Hasebe K, Satoh M, Tsujimoto Y, Takada T, Honda M, Matsumiya K, Fujioka H, Okihara K, Miki T: [Simultaneous bilateral testicular tumors with different cell types: a case report]. Hinyokika Kiyo; 2005 Jul;51(7):475-8
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Simultaneous bilateral testicular tumors with different cell types: a case report].
  • The bilateral testicular tumors were palpated and visualized by ultrasound and magnetic resonance imaging (right phi5 cm, left phi2 cm in diameter).
  • Computed tomography revealed a metastatic lymph node around the abdominal aorta (3 x 3 x 10 cm in size).
  • Enucleation of the left testicular tumor was not performed because of its irregular demarcation.
  • Histological examination revealed typical seminoma of the right testis and embryonal carcinoma of the left testis.
  • Retroperitoneal lymph node dissection was performed after 4 courses of systematic chemotherapy (bleomycin, etoposide, platinum).
  • The postoperative course was good and uneventful at 16 months under androgen replacement therapy without disease recurrence.
  • [MeSH-major] Neoplasms, Multiple Primary / pathology. Seminoma / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16119814.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Kempkensteffen C, Hinz S, Jäger T, Weikert S, Krause H, Schostak M, Christoph F, Strenziok R, Miller K, Schrader M: [Expression levels of the IAP antagonists XAF1, Smac/DIABLO and HtrA2 in testicular germ cell tumours]. Aktuelle Urol; 2008 Nov;39(6):436-41
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression levels of the IAP antagonists XAF1, Smac/DIABLO and HtrA2 in testicular germ cell tumours].
  • [Transliterated title] Expression der pro-apoptotischen Apoptoseinhibitor-(IAP)Antagonisten XAF1, Smac/DIABLO und HtrA2 in Keimzelltumoren des Hodens.
  • We examined the mRNA-expression of these pro-apoptotic parameters in testicular germ cell tumors (TGCT) and normal testicular tissue and correlated their expression levels to clinicopathological tumour features.
  • MATERIAL AND METHODS: Real-time RT-PCR was used to quantify the mRNA-expression of XAF1, Smac/DIABLO and HtrA2 in normal testicular tissue (n = 18), carcinoma in situ (n = 4), seminomas (n = 64), and non-seminomatous germ cell tumors (n = 35).
  • RESULTS: Compared to normal testicular tissue, the expression levels of XAF1 were increased in TGCT (p < 0.001), whereas those of Smac/DIABLO and HtrA2 were decreased (p < 0.001 and p < 0.001).
  • Smac/DIABLO expression levels showed a significant trend towards a gradual decrease from normal testicular tissue to CIS and seminomas and finally to NSGCT (p < 0.001).
  • Moreover, XAF1 and HtrA2 expression levels gradually increased with progression of clinical tumour stage in seminoma patients (p = 0.001 and p = 0.018), their expression levels being strongly intercorrelated (Spearman rho correlation coefficient: 0.674; p < 0.001).
  • CONCLUSION: These data suggest that a down-regulation of Smac/DIABLO and HtrA2 is implicated in the development and progression of TGCT, whereas overexpression of XAF1 in TGCT might contribute to their extraordinary sensitivity to chemotherapy.
  • Regarding the additional correlation of XAF1 and HtrA2 expression with clinical tumour stage in seminoma patients, it appears reasonable to further evaluate these three IAP antagonists as molecular parameters for the prediction of treatment response and prognosis of TGCT patients.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / genetics. Inhibitor of Apoptosis Proteins / antagonists & inhibitors. Inhibitor of Apoptosis Proteins / genetics. Intracellular Signaling Peptides and Proteins / genetics. Mitochondrial Proteins / genetics. Neoplasm Proteins / genetics. Neoplasms, Germ Cell and Embryonal / genetics. Serine Endopeptidases / genetics. Testicular Neoplasms / genetics
  • [MeSH-minor] Biopsy. Carcinoma in Situ / genetics. Carcinoma in Situ / pathology. Carcinoma, Embryonal / genetics. Carcinoma, Embryonal / pathology. Disease Progression. Down-Regulation / genetics. Humans. Male. Prognosis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Seminoma / genetics. Seminoma / pathology. Teratocarcinoma / genetics. Teratocarcinoma / pathology. Testis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18979398.001).
  • [ISSN] 1438-8820
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DIABLO protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Mitochondrial Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / XAF1 protein, human; EC 3.4.21.- / Omi serine protease; EC 3.4.21.- / Serine Endopeptidases
  •  go-up   go-down


15. Soriano Sarrió P, Chirivella I, Navarro Fos S: [Coexistence of two germinal cell tumors, seminomatous and nonseminomatous, with an uncommon clinical presentation]. Arch Esp Urol; 2008 Jun;61(5):626-30
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The existence of non seminomatous mixed germ cell tumors of the testis is a frequent event in urologic oncology.
  • METHODS: We present a case of pure classic seminoma of the testis with a lymph node metastasis of pure embryonal carcinoma, with confirmatory immuohistochemical study and clinical outcome of the patient.
  • Tumor markers were negative and the biopsy performed discovered a lymph node metastasis of embryonal carcinoma of probable testicular origin.
  • Ultrasound revealed a 6 mm hypoechoic nodule in the right testis.
  • Orchyectomy was performed and pathologic analysis demonstrated a tumor, 1 cm of diameter, histopathologically compatible with classical seminoma with pagetoid extension to rete testis.
  • Currently the patient is being treated with chemotherapy.
  • CONCLUSION: The interest of the case is to remark an unusual aggressive clinical presentation as well as to perform a bibliographic review with emphasis in the theories regarding heterogeneous differentiation and spontaneous regression of germ cell tumors of the testis.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Multiple Primary / pathology. Testicular Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18709819.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


16. Sloetjes KG, van den Bergh JP, Wesseling P, Otten BJ, Pieters GF, Hermus AR: [Clinical presentation, treatment, and follow-up of 32 patients with a primary intracranial germinoma, registered during the previous 15 years in the Dutch Pathological-Anatomical National Automated Archive (PALGA)]. Ned Tijdschr Geneeskd; 2000 Nov 18;144(47):2264-8
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical presentation, treatment, and follow-up of 32 patients with a primary intracranial germinoma, registered during the previous 15 years in the Dutch Pathological-Anatomical National Automated Archive (PALGA)].
  • OBJECTIVE: Evaluation of clinical presentation, treatment and follow-up of patients with intracranial germinoma in the Netherlands.
  • Informed consent was obtained from 32 of the 44 patients with respect to studying their medical records for age, symptoms at presentation, diagnostic investigations, presence of tumour markers, treatment and follow up.
  • Thirty-one patients were treated with radiotherapy, one with combined radiotherapy and chemotherapy and one surgically.
  • One patient developed an intracranial embryonal carcinoma and another a testis seminoma.
  • CONCLUSION: At the time of this study 84% of all patients treated with radiotherapy were disease-free.
  • Although the percentage patients who had recovered after treatment (surgical and radiotherapy) was high, many patients either already had or subsequently developed neurological and endocrinological deficiencies.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Germinoma / diagnosis. Germinoma / therapy
  • [MeSH-minor] Adolescent. Adult. Cause of Death. Child. Diagnosis, Differential. Disease-Free Survival. Endocrine System Diseases / etiology. Female. Humans. Intracranial Hypertension / etiology. Male. Neoplasms, Germ Cell and Embryonal / etiology. Netherlands. Ocular Motility Disorders / etiology. Recurrence. Registries. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Germinoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11109472.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] NETHERLANDS
  •  go-up   go-down


17. Looijenga LH, Gillis AJ, Stoop HJ, Hersmus R, Oosterhuis JW: Chromosomes and expression in human testicular germ-cell tumors: insight into their cell of origin and pathogenesis. Ann N Y Acad Sci; 2007 Dec;1120:187-214
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomes and expression in human testicular germ-cell tumors: insight into their cell of origin and pathogenesis.
  • Within the testis, three types of GCTs can be diagnosed: type I (teratomas and yolk-sac tumors of neonates and infants); type II (seminomas and nonseminomas); type III (spermatocytic seminomas).
  • Here the focus is on the type II GCTs, the most frequent type in the adult testis (so-called TGCTs).
  • In the testis, they originate from the malignant counterpart of primordial germ cells/gonocytes, referred to as carcinoma in situ (CIS)/intratubular germ-cell neoplasia unclassified (ITGCNU).
  • CIS/ITGCNU and seminomatous cells are characterized by expression of OCT3/4 and NANOG, while in addition embryonal carcinoma expresses SOX2, all identified as transcription factors related to pluripotency in embryonic stem (ES) cells.
  • With the exception of teratomas, most histological elements of TGCTs are sensitive for (cisplatin-based) chemotherapy; CIS/ITGCNU and seminoma cells are also sensitive to DNA damage induced by irradiation.
  • The unusual presence of wild-type P53 in TGCTs is explained by specific expression of a cluster of micro-RNAs (miRNAs), that is, hsa-miR 371-373, also expressed in ES cells, which prevents P53-driven cellular senescence upon oncogenic stress.
  • [MeSH-major] Chromosomes, Human. Gene Expression Regulation, Neoplastic. Neoplasms, Germ Cell and Embryonal / etiology. Neoplasms, Germ Cell and Embryonal / genetics. Neoplastic Stem Cells / physiology. Testicular Neoplasms / etiology. Testicular Neoplasms / genetics
  • [MeSH-minor] Animals. Disease Progression. Embryonal Carcinoma Stem Cells. Epigenesis, Genetic / physiology. Humans. Male. Models, Biological. Stem Cells / physiology

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17911410.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 206
  •  go-up   go-down


18. Otite U, Webb JA, Oliver RT, Badenoch DF, Nargund VH: Testicular microlithiasis: is it a benign condition with malignant potential? Eur Urol; 2001 Nov;40(5):538-42
MedlinePlus Health Information. consumer health - Testicular Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular microlithiasis: is it a benign condition with malignant potential?
  • OBJECTIVE: To review the findings of testicular ultrasonography (US) in patients referred for testicular symptoms including pain, swelling and infertility, and to determine the prevalence of testicular microlithiasis (TM) and ist relevance to the development of testicular cancer.
  • METHODS: Records of 3,026 patients referred for testicular US between 1994 and 1999 were evaluated.
  • The indications for testicular US diagnosis, management and relevant histological details were obtained from medical records.
  • Patients with TM had an annual sonographic follow-up unless they had testicular cancer, in which case follow-up repeat US with clinical reviews was more frequent.
  • Sixteen of these patients had testicular malignancy (30%).
  • One patient with a small testis developed a seminoma while under surveillance.
  • Another patient with metastatic embryonal-cell carcinoma at initial diagnosis was found to have a seminoma 4 years following chemotherapy.
  • The relative risk of testicular tumours in the presence of TM was 13.2 (confidence interval 8.3-21.5).
  • CONCLUSION: TM can no longer be regarded simply as a benign condition because of its association with testicular malignancy.
  • In our series, 2 patients (5.2%) developed interval testicular cancers during follow-up US.
  • In rare instances of radiologically indeterminate cases, biopsy of the testis may be necessary.
  • [MeSH-major] Calculi / complications. Precancerous Conditions. Testicular Diseases / complications. Testicular Neoplasms / etiology

  • Genetic Alliance. consumer health - Testicular microlithiasis.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11752862.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


19. Mikuz G: [WHO classification of testicular tumors]. Verh Dtsch Ges Pathol; 2002;86:67-75
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [WHO classification of testicular tumors].
  • Twenty years after the first edition (1977), the WHO has presented the updated version of the "Histological typing of testis tumours".
  • Such atypical cells appear in the tubules adjacent to the germ cell tumors, in some few cases (6%) also in the contra lateral healthy gonad and rarely in infertile men (1%).
  • The precursor lesion can progress to franc germ cell tumor starting probably with seminoma, which still maintain the capability of differentiation (pluripotente cells) in all other types of non-seminomatous germ cell tumors.
  • Seminoma with syncytiotrophoblastic cells is a variant which should not be confused with choriocarcinoma.
  • This is a harmless name for an extremely dangerous tumor in which one tissue overgrows the other and gives rise to somatic type sarcomas or carcinomas.
  • Such tumors do not respond like germ cell tumors to the usual chemotherapy.
  • Treatment should be tailored according to that used in standard management of the respective sarcoma or carcinoma.
  • In the comments it is mentioned that the testis carcinoid could be a part of teratoma, but the diagnosis is listed in the group of "miscellaneous" tumors together with tumors of ovarian epithelial type.
  • This is a very questionable decision because the normal testis does not contain neuroendocrine cells from which carcinoids would have to be able to develop.
  • The patients have cardiac myxomas, spotty skin pigmentation, hormone active nodular hyperplasia of the adrenals and soft tissue myxomas.
  • For the therapy of germ cell tumor an assessment of risk factors found by the pathologists is extremely important.
  • The most important independent predictors of relapse are tumor invasion of blood or lymph-vessels, absence of yolk sac elements and the presence of an embryonal carcinoma component.
  • In the absence of such predictors a surveillance policy allows some patients to forgo chemotherapy.
  • [MeSH-major] Testicular Neoplasms / classification

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12647353.001).
  • [ISSN] 0070-4113
  • [Journal-full-title] Verhandlungen der Deutschen Gesellschaft für Pathologie
  • [ISO-abbreviation] Verh Dtsch Ges Pathol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 48
  •  go-up   go-down


20. Opot EN, Magoha GA: Testicular cancer at Kenyatta National Hospital, Nairobi. East Afr Med J; 2000 Feb;77(2):80-5
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular cancer at Kenyatta National Hospital, Nairobi.
  • OBJECTIVE: To determine the prevalence, clinical characteristics, management methods and prognosis of testicular cancer at Kenyatta National Hospital.
  • DESIGN: Retrospective case study of testicular cancer patients over a fifteen year period.
  • PARTICIPANTS: All histologically confirmed testicular cancer patients recorded at the Histopathology Department of Kenyatta National Hospital between 1983 and 1997.
  • Thirty one patients (79.49%) presented with painless testicular swellings, eleven (28.08%) with pain, nine (23.08%) with scrotal heaviness, six (15.38%) with abdominal swellings and one (2.56%) each with gynaecomastia and eye swelling.
  • On examination 32 patients (82.05%) had testicular masses, ten (25.64%) had abdominal masses, seven (17.91%) had supraclavicular and cervical lymphadenopathy, and one each (2.56%) had gynaecomastia and eye mass respectively.
  • More than eighty nine per cent had germ cell cancers with seminoma accounting for 67.35%, teratoma 12.24%, embroyonal carcinoma 8.16%, rhabdomyosarcoma 6.12% and malignant germ cell tumour, orchioblastoma and dysgerminoma each accounted for 2.04%.
  • Three patients (7.7%) had orchidectomy and radiotherapy and chemotherapy, sixteen (41.03%) had orchidectomy and radiotherapy, six (15.38%) had orchidectomy and chemotherapy, ten (25.64%) had radiotherapy and chemotherapy, three (7.7%) and two (5.13%) had only chemotherapy and radiotherapy respectively.
  • No cisplastin based chemotherapy regime was used.
  • Cisplastin based chemotherapy with up to 90% cure rates should be included as a component of testicular cancer management at Kenyatta National Hospital.
  • This retrospective study was undertaken to determine the prevalence, clinical characteristics, management methods and prognosis of testicular cancer at Kenyatta National Hospital, Nairobi.
  • All histologically confirmed testicular cancer patients recorded at the Histopathology Department between 1993 and 1997 were analyzed.
  • The clinical symptoms presented were painless testicular swelling (n = 31, 79.49%), testicular pain (n = 11, 28.08%), scrotal heaviness (n = 9, 23.08%), abdominal swelling (n = 6, 15.38%), gynecomastia (n = 1, 2.56%), and eye swelling (n = 1, 2.56%).
  • On examination, 32 patients (82.05%) had testicular masses, 10 (25.64%) had abdominal masses, 7 (17.91%) had supraclavicular and cervical lymphadenopathy, 1 had gynecomastia, and 1 had an orbital mass.
  • More than 89% of patients had germ cell cancers with seminoma accounting for 67.35%, teratoma for 12.24%, embryonal carcinoma for 8.16%, rhabdomyosarcoma for 6.12%, and malignant germ cell tumor, orchioblastoma, and dysgerminoma each accounting for 2.04%.
  • The various methods of treatment include orchidectomy and radiotherapy and chemotherapy in 3 patients (7.7%), orchidectomy and radiotherapy in 16 patients (41.03%), orchidectomy and chemotherapy in 6 patients (15.38%), and radiotherapy and chemotherapy in 10 patients (25.64%).
  • No cisplatin-based chemotherapy was used.
  • Hence, cisplatin-based chemotherapy with up to 90% cure rates should be included in the testicular cancer management in this hospital.
  • [MeSH-major] Testicular Neoplasms / diagnosis. Testicular Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Child. Child, Preschool. Combined Modality Therapy. Hospitals, Teaching. Humans. Incidence. Kenya / epidemiology. Male. Middle Aged. Orchiectomy. Prognosis. Referral and Consultation. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10774080.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] KENYA
  • [Other-IDs] PIP/ 149564; POP/ 00296083
  • [Keywords] PIP ; Cancer (major topic) / Clinical Research (major topic) / Prevalence (major topic) / Research Report (major topic) / Retrospective Studies (major topic) / Signs And Symptoms (major topic) / Testis (major topic) / Treatment (major topic) / Africa / Africa South Of The Sahara / Biology / Developing Countries / Diseases / Eastern Africa / English Speaking Africa / Genitalia / Genitalia, Male / Kenya / Measurement / Neoplasms / Physiology / Research Methodology / Studies / Urogenital System
  • [General-notes] PIP/ TJ: EAST AFRICAN MEDICAL JOURNAL.
  •  go-up   go-down


21. Verdonk RC, Enting RH, Janmaat M, Schroder CP, Sleijfer DT, Gietema JA: Weakness and numbness after chemotherapy for metastatic non-seminoma testis: a new neurological complication. Acta Oncol; 2008;47(8):1596-8
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weakness and numbness after chemotherapy for metastatic non-seminoma testis: a new neurological complication.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Embryonal / drug therapy. Demyelinating Diseases / chemically induced. Guillain-Barre Syndrome / chemically induced. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Etoposide / administration & dosage. Humans. Hypesthesia / chemically induced. Hypesthesia / drug therapy. Male

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Guillain-Barre Syndrome.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18607855.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down






Advertisement